Covishield: Manufacturer, dose schedule, efficacy rate, possible side effects and price
India
Updated: Saturday, January 16, 2021, 15:26 [IST]
New Delhi, Jan 16: Covishield vaccine has been developed by the University of Oxford and British-Swedish pharmaceutical company AstraZeneca.
Adar Poonawalla, Chief Executive Officer, Serum Institute of India (SII) which is British-Swedish pharma giant AstraZeneca s manufacturing partner - said that the vaccine would be 90 to 95 per cent effective if the two shots are parted by around 2-3 months.
File Photo
The vaccine is being touted as one of the most promising vaccines for India where cost and logistics play a big roll. You ll be hearing some good news from the UK very soon. It would be a 90-95 per cent effective vaccine if you just keep a two-to-three months gap between dose 1 and dose 2. They will make that public with documentation.
Vaccine beneficiaries must rest for an hour, advises government
India
Updated: Saturday, January 16, 2021, 15:24 [IST]
New Delhi, Jan 16: All beneficiaries of the vaccine against COVIDD-19 have been asked to rest for an hour after getting vaccinated.
The Health Ministry said that all vaccine sites have three marked areas for waiting, vaccination and observation. After one gets the jab, it is advised that they do not leave the site immediately as the effects of the shot, if any will be monitored at the vaccine site. Covid-19-appropriate behaviour, including the wearing of masks and social distancing, is to be followed, the ministry also said.
Explained: How two COVID-19 shots, launched in India work
India
Updated: Saturday, January 16, 2021, 15:24 [IST]
New Delhi, Jan 16: India on Saturday launched one of the world s biggest vaccination programmes with COVID vaccines manufactured in the country - one developed by Oxford University and AstraZeneca, the other by Bharat Biotech International with a state-run institute.
It is reportedly said that three crore health and other frontline workers, followed by about 27 crore older than 50 or considered high-risk would receive COVID-19 vaccine.
Covishield
Covishield is developed by the University of Oxford and British-Swedish pharmaceutical company AstraZeneca and manufactured by the Pune-based Serum Institute of India. This vaccine has emerged as the most promising vaccine for countries like India where cost and logistics are a significant consideration.
According to the guidelines, all government and non-government health workers will be vaccinated first. While nine lakh health workers are scheduled to receive the shots in the first three days, those who do not get it for any reason will be vaccinated on the fourth day.